July 1, 2014 | Israeli bio-pharmaceutical company Red Hill Biopharma acquired Phase II oncology drug, Mesupron from Wilex AG. Mesupron has already completed a number of Phase I and Phase II clinical trials for the treatment of non-metastatic pancreatic cancer. Red Hill has acquired the exclusive development and commercialization rights for Mesupron, except in China, Hong Kong, Taiwan and Macao, for nearly $1 million from Wilex AG. The Israeli company, founded in 2009, will be responsible for the development, regulation and commercialization of Mesupron.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Red Algae Can Treat Wounds And Infections
January 26, 2023

Freight Planner Lists on Nasdaq And Raises $80M
January 26, 2023

$6M Investment For “Lettuce Milk” Startup
January 25, 2023

Israel Has World’s Best Value Internet
January 25, 2023
Facebook comments